HNRNPA1 and cancer: There is a study that suggested that cisplatin and paclitaxel promote miR-522 secretion from cancer-associated fibroblasts by activating the USP7/hnRNPA1 axis, leading to arachidonate lipoxygenase 15 suppression and decreased lipid-ROS accumulation in cancer cells, and ultimately resulting in decreased chemo-sensitivity [37].